Clinical Trial Update: Ethyl-EPA Treatment of Prodromal Patients [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial of Ethyl-EPA for prodromal schizophrenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Ethyl-EPA (ethyl eicosapentaenoic acid)

Snippet

Sponsor: Yale University | Conditions: Schizophrenia Prodrome | Phase 2, Phase 3 | Status: COMPLETED